• The study primarily investigates the effect of copaxone on fatigue during treatment, compared to baseline in patients with relapsing-remitting multiple sclerosis.
• Secondary outcome measures are:disability, relapse rate, quality of life and depression.

Inclusion Criteria:

• relapsing-remitting Multiple Sclerosis (MS),
• at least 2 relapses in previous 2 years prior to copaxone or interferon beta treatment,
• ambulant patients i.e disability score EDSS MAX 5,5,
• clinically stable MS
• relapse free and steroid free at least 30 days prior to start copaxone treatment

Exclusion Criteria:

• hypersensitivity to glatiramer acetate or mannitol,
• pregnancy,
• fertile female not willing to use effective contraception,
• previous treatment with copaxone

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.